Drugs / GSK5784283
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07712393 | Jul 2026 → Apr 2027 expected | asthma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06748053 | Feb 2025 → Jul 2026 overdue | asthma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK5784283 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07712393 ↗ |
| Action | Inhibit | “GSK5784283 blocks the action of an inflammatory protein called TSLP” NCT06748053 ↗ |
| Modality | Monoclonal antibody | “Anti-TSLP Antibody (GSK5784283)” NCT06748053 ↗ |
| Route | Subcutaneous | “GSK5784283 Administered by Subcutaneous Injection” NCT07712393 ↗ |